[go: up one dir, main page]

TN2009000104A1 - Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor - Google Patents

Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor

Info

Publication number
TN2009000104A1
TN2009000104A1 TN2009000104A TN2009000104A TN2009000104A1 TN 2009000104 A1 TN2009000104 A1 TN 2009000104A1 TN 2009000104 A TN2009000104 A TN 2009000104A TN 2009000104 A TN2009000104 A TN 2009000104A TN 2009000104 A1 TN2009000104 A1 TN 2009000104A1
Authority
TN
Tunisia
Prior art keywords
growth factor
factor receptor
epidermal growth
therapeutic compositions
boosting
Prior art date
Application number
TN2009000104A
Other languages
English (en)
Inventor
Hidalgo Greta Garrido
Ramirez Belinda Sanchez
Gomez Audry Fernandez
Requena Alejandro Lopez
Molina Luis Enrique Fernandez
Rodriguez Rolando Perez
Delgado Irene Beausoleil
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40223744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000104(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of TN2009000104A1 publication Critical patent/TN2009000104A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TN2009000104A 2006-09-29 2009-03-27 Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor TN2009000104A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20060190A CU23612A1 (es) 2006-09-29 2006-09-29 Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico
PCT/CU2007/000017 WO2008037225A1 (fr) 2006-09-29 2007-09-27 Compositions thérapeutiques permettant d'augmenter l'effet d'une thérapie aux anticorps contre le récepteur du facteur de croissance épidermique

Publications (1)

Publication Number Publication Date
TN2009000104A1 true TN2009000104A1 (en) 2010-08-19

Family

ID=40223744

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2009000104A TN2009000104A1 (en) 2006-09-29 2009-03-27 Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor

Country Status (19)

Country Link
US (1) US20100047207A1 (fr)
EP (1) EP2070547B1 (fr)
KR (1) KR101482957B1 (fr)
CN (2) CN102940883A (fr)
AR (1) AR063011A1 (fr)
AU (1) AU2007302429B2 (fr)
BR (1) BRPI0717142A2 (fr)
CA (1) CA2664795C (fr)
CL (1) CL2007002797A1 (fr)
CO (1) CO6160338A2 (fr)
CR (1) CR10753A (fr)
CU (1) CU23612A1 (fr)
MA (1) MA30811B1 (fr)
MX (1) MX2009003159A (fr)
PE (1) PE20080674A1 (fr)
TN (1) TN2009000104A1 (fr)
TR (1) TR200902344T1 (fr)
UY (1) UY30616A1 (fr)
WO (1) WO2008037225A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI500630B (zh) * 2008-06-20 2015-09-21 Centro Inmunologia Molecular 具有細胞生長抑制功效之表皮生長因子受體（ｅｇｆｒ）抑制劑類及彼等於腫瘤治療上之用途
CN103536917B (zh) * 2013-10-30 2015-03-11 苏州丁孚靶点生物技术有限公司 干扰素在治疗肿瘤中的用途及相关的产品和方法
MY188446A (en) * 2015-07-27 2021-12-09 Innocimab Pte Ltd Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
DE69324671D1 (de) * 1992-02-10 1999-06-02 Interferon Sciences Inc Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
BR0209147A (pt) * 2001-05-08 2004-06-08 Merck Patent Gmbh Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
US20060134064A1 (en) * 2004-12-20 2006-06-22 David Goldstein Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions

Also Published As

Publication number Publication date
AR063011A1 (es) 2008-12-23
CA2664795C (fr) 2014-06-17
BRPI0717142A2 (pt) 2013-10-15
PE20080674A1 (es) 2008-07-23
EP2070547B1 (fr) 2013-04-24
CN101678099A (zh) 2010-03-24
KR20090058566A (ko) 2009-06-09
CO6160338A2 (es) 2010-05-20
EP2070547A1 (fr) 2009-06-17
CL2007002797A1 (es) 2008-04-18
CA2664795A1 (fr) 2008-04-03
AU2007302429B2 (en) 2013-10-03
CU23612A1 (es) 2010-12-08
CN102940883A (zh) 2013-02-27
EP2070547A4 (fr) 2011-11-02
MX2009003159A (es) 2009-04-06
CR10753A (es) 2009-10-15
MA30811B1 (fr) 2009-10-01
TR200902344T1 (tr) 2009-08-21
WO2008037225A1 (fr) 2008-04-03
KR101482957B1 (ko) 2015-01-15
AU2007302429A1 (en) 2008-04-03
US20100047207A1 (en) 2010-02-25
UY30616A1 (es) 2008-05-02

Similar Documents

Publication Publication Date Title
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
TW200639182A (en) Antibody variants and uses thereof
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
TW200501982A (en) Immunoglobulin variants and uses thereof
MX2010001378A (es) Uso terapeutico de anticuerpos del receptor anti-tweak.
UA109633C2 (uk) Антитіло людини проти тканинного фактора
ZA200609407B (en) Monoclonal antibodies to hepatocyte growth factor
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
WO2009135861A3 (fr) Anticorps humanisés contre l'interféron-alpha humain
TNSN06133A1 (en) Immunoglobulin variants and uses thereof
TN2009000104A1 (en) Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor
UA102085C2 (ru) ВЫДЕЛЕННОЕ МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С hGM-CSF, И КОМПОЗИЦИЯ МЕДИЦИНСКОГО НАЗНАЧЕНИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ